Alnylam and Cubist have reported preliminary data from their Phase II study of Aln-Rsv01, an RNAi therapeutic in development for the treatment of respiratory syncytial virus (RSV) infection.
The Phase II study was a randomized, double-blind study of inhaled Aln-Rsv01 or placebo in adult lung transplant patients infected with RSV.
In the study, 24 lung transplant patients with confirmed RSV infection were randomized to receive inhaled Aln-Rsv01 or placebo once daily for three consecutive days.
Overall, the study achieved its primary objective of demonstrating safety and tolerability of Aln-Rsv01 over 30 days post treatment.
Akshay Vaishnaw, Senior Vice President of Clinical Research at Alnylam, said: “We are pleased with the preliminary results of our Phase II study as we have documented for the first time the safety and tolerability of inhaled Aln-Rsv01 in naturally infected patients, which we consider an important step forward in the advancement of our overall Aln-Rsv program toward both pediatric and adult patient populations.”